🕵️ Kiora Pharmaceuticals Inc ($KPRX)
SEC insider & ownership activity, last 12 months · CIK 1372514 · every row links its SEC filing
Insiders were quiet over the last 12 months – no open-market buys or sells. No red-flag 8-Ks in the window.
Insider flow
0 buyers, $0 (0 lots) · 0 sellers, $0 (0 lots)
No open-market insider transactions in the last 12 months.
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | 10.0% | 13G | Aug 10, 2026 | filing ↗ | |
| Joseph Edelman | 10.0% | 13G | Aug 10, 2026 | filing ↗ | |
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | 13G | Aug 10, 2026 | filing ↗ | |
| Alyeska Investment Group, L.P. | 10.0% | 13G | May 15, 2026 | filing ↗ | |
| Alyeska Fund GP, LLC | 10.0% | 13G | May 15, 2026 | filing ↗ | |
| Anand Parekh | 10.0% | 13G | May 15, 2026 | filing ↗ | |
| Nantahala Capital Management, LLC | 10.0% | 13G | Aug 14, 2026 | filing ↗ | |
| Wilmot B. Harkey | 10.0% | 13G | Aug 14, 2026 | filing ↗ | |
| Daniel Mack | 10.0% | 13G | Aug 14, 2026 | filing ↗ | |
| Rosalind Advisors, Inc. | 9.9% | 13G | Feb 11, 2026 | filing ↗ | |
| Salamon Steven A. J. | 9.9% | 13G | Feb 11, 2026 | filing ↗ | |
| Aharon Gil | 9.9% | 13G | Feb 11, 2026 | filing ↗ | |
| Rosalind Master Fund L.P. | 9.9% | 13G | Feb 11, 2026 | filing ↗ | |
| ADAR1 Capital Management, LLC | 9.9% | 13G | Aug 14, 2026 | filing ↗ | |
| ADAR1 Capital Management GP, LLC | 9.9% | 13G | Aug 14, 2026 | filing ↗ | |
| Daniel Schneeberger | 9.9% | 13G | Aug 14, 2026 | filing ↗ |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Officer/director changes (5.02) | Sep 8, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Sep 8, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 8, 2026 | filing ↗ |
| Material agreement (1.01) | Aug 19, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Aug 19, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 19, 2026 | filing ↗ |
| Earnings (2.02) | Aug 7, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 7, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jun 18, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 18, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jun 10, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 10, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 10, 2026 | filing ↗ |
| Earnings (2.02) | May 8, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 8, 2026 | filing ↗ |
| Material agreement (1.01) | Apr 3, 2026 | filing ↗ |
| Unregistered equity sale (3.02) | Apr 3, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Apr 3, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 3, 2026 | filing ↗ |
| Officer/director changes (5.02) | Apr 1, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Apr 1, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 1, 2026 | filing ↗ |
| Earnings (2.02) | Mar 25, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 25, 2026 | filing ↗ |
| Earnings (2.02) | Nov 7, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 7, 2025 | filing ↗ |